Literature DB >> 15210186

Mutations affecting liver development and function in Medaka, Oryzias latipes, screened by multiple criteria.

Tomomi Watanabe1, Satoshi Asaka, Daiju Kitagawa, Kota Saito, Ryumei Kurashige, Takao Sasado, Chikako Morinaga, Hiroshi Suwa, Katsutoshi Niwa, Thorsten Henrich, Yukihiro Hirose, Akihito Yasuoka, Hiroki Yoda, Tomonori Deguchi, Norimasa Iwanami, Sanae Kunimatsu, Masakazu Osakada, Felix Loosli, Rebecca Quiring, Matthias Carl, Clemens Grabher, Sylke Winkler, Filippo Del Bene, Joachim Wittbrodt, Keiko Abe, Yousuke Takahama, Katsuhito Takahashi, Toshiaki Katada, Hiroshi Nishina, Hisato Kondoh, Makoto Furutani-Seiki.   

Abstract

We report here mutations affecting various aspects of liver development and function identified by multiple assays in a systematic mutagenesis screen in Medaka. The 22 identified recessive mutations assigned to 19 complementation groups fell into five phenotypic groups. Group 1, showing defective liver morphogenesis, comprises mutations in four genes, which may be involved in the regulation of growth or patterning of the gut endoderm. Group 2 comprises mutations in three genes that affect the laterality of the liver; in kendama mutants of this group, the laterality of the heart and liver is uncoupled and randomized. Group 3 includes mutations in three genes altering bile color, indicative of defects in hemoglobin-bilirubin metabolism and globin synthesis. Group 4 consists of mutations in three genes, characterized by a decrease in the accumulation of fluorescent metabolite of a phospholipase A(2) substrate, PED6, in the gall bladder. Lipid metabolism or the transport of lipid metabolites may be affected by these mutations. Mutations in Groups 3 and 4 may provide animal models for relevant human diseases. Group 5 mutations in six genes affect the formation of endoderm, endodermal rods and hepatic bud from which the liver develops. These Medaka mutations, identified by morphological and metabolite marker screens, should provide clues to understanding molecular mechanisms underlying formation of a functional liver.

Entities:  

Mesh:

Year:  2004        PMID: 15210186     DOI: 10.1016/j.mod.2004.04.004

Source DB:  PubMed          Journal:  Mech Dev        ISSN: 0925-4773            Impact factor:   1.882


  8 in total

1.  A new model system swims into focus: using the zebrafish to visualize intestinal metabolism in vivo.

Authors:  Juliana D Carten; Steven A Farber
Journal:  Clin Lipidol       Date:  2009-08-01

2.  Parameters and efficiency of direct gene disruption by zinc finger nucleases in medaka embryos.

Authors:  Xi Zhang; Guijun Guan; Jianbin Chen; Kiyoshi Naruse; Yunhan Hong
Journal:  Mar Biotechnol (NY)       Date:  2013-10-23       Impact factor: 3.619

Review 3.  Zebrafish lipid metabolism: from mediating early patterning to the metabolism of dietary fat and cholesterol.

Authors:  Jennifer L Anderson; Juliana D Carten; Steven A Farber
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

4.  Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation.

Authors:  Shinya Kuwashiro; Shuji Terai; Toshiyuki Oishi; Koichi Fujisawa; Toshihiko Matsumoto; Hiroshi Nishina; Isao Sakaida
Journal:  Cell Tissue Res       Date:  2011-02-16       Impact factor: 5.249

Review 5.  Lessons from "lower" organisms: what worms, flies, and zebrafish can teach us about human energy metabolism.

Authors:  Amnon Schlegel; Didier Y R Stainier
Journal:  PLoS Genet       Date:  2007-11       Impact factor: 5.917

6.  Zebrafish yolk lipid processing: a tractable tool for the study of vertebrate lipid transport and metabolism.

Authors:  Rosa L Miyares; Vitor B de Rezende; Steven A Farber
Journal:  Dis Model Mech       Date:  2014-05-08       Impact factor: 5.758

7.  Comparative epigenomics in distantly related teleost species identifies conserved cis-regulatory nodes active during the vertebrate phylotypic period.

Authors:  Juan J Tena; Cristina González-Aguilera; Ana Fernández-Miñán; Javier Vázquez-Marín; Helena Parra-Acero; Joe W Cross; Peter W J Rigby; Jaime J Carvajal; Joachim Wittbrodt; José L Gómez-Skarmeta; Juan R Martínez-Morales
Journal:  Genome Res       Date:  2014-04-07       Impact factor: 9.043

Review 8.  Animal models for target diseases in gene therapy--using DNA and siRNA delivery strategies.

Authors:  Ian S Blagbrough; Chiara Zara
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.